Holen Sie sich die Stockscreener-App
9.44
0.47%
-0.04
Delcath Systems Inc Aktie (DCTH) Neueste Nachrichten
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $250,000 from Inve - Yahoo
The Technical Signals Behind (DCTH) That Institutions Follow - Stock Traders Daily
Delcath Systems Charts Profitable Path Amid Heavy Investment - TipRanks
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Delcath Systems (DCTH) - The Globe and Mail
Can Delcath Systems Inc expand into new marketsQuarterly Earnings Report & Risk Managed Trade Strategies - baoquankhu1.vn
Insider Buying: Sandra Pennell Acquires Shares of Delcath Systems Inc (DCTH) - GuruFocus
Fundamentals Check: Is Delcath Systems Inc a strong candidate for buy and holdMarket Performance Report & Accurate Intraday Trading Signals - baoquankhu1.vn
Propel Bio Management LLC Buys 212,457 Shares of Delcath Systems, Inc. $DCTH - MarketBeat
Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology - Yahoo Finance
HC Wainwright Lowers Earnings Estimates for Delcath Systems - MarketBeat
Delcath announces publication of liver cancer treatment trial - Investing.com
Delcath announces publication of liver cancer treatment trial By Investing.com - Investing.com Canada
Delcath Highlights CHOPIN Phase 2 Results in Uveal Melanoma - TipRanks
Insider Buying: Gerard Michel Acquires Additional Shares of Delc - GuruFocus
CHOPIN uveal melanoma trial data in Lancet boosts Delcath (Nasdaq: DCTH) - Stock Titan
[Form 4] DELCATH SYSTEMS, INC. Insider Trading Activity - Stock Titan
Delcath Systems announces publication of Chopin clinical trial results in The Lancet Oncology - marketscreener.com
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2025 Earnings Call Transcript - Insider Monkey
Delcath Systems Announces Publication Of Chopin Clinical Trial Results In The Lancet Oncology - TradingView
Liver-directed therapy plus immunotherapy extends survival in uveal melanoma - Stock Titan
FY2029 EPS Forecast for Delcath Systems Decreased by Analyst - MarketBeat
Delcath Systems Reports Record 2025 Results, Outlines 2026 Growth Plan - National Today
Delcath: Fundamentals Intact, Despite Share Price Weakness (NASDAQ:DCTH) - Seeking Alpha
Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Uveal Melanoma Treatment Market Set to Soar: Breakthrough - openPR.com
DCTH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Precision Trading with Delcath Systems Inc. (DCTH) Risk Zones - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Baxter International (BAX), Nautilus Biotechnolgy (NAUT) and Delcath Systems (DCTH) - The Globe and Mail
Delcath Systems (NASDAQ:DCTH) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Craig-Hallum cuts Delcath Systems stock price target on revenue guide - Investing.com Canada
BTIG lowers Delcath Systems stock price target to $19 on guidance - Investing.com Australia
Delcath Systems (DCTH) First Profitable Year Tests Lofty 115.7x P/E Narrative - simplywall.st
BTIG Maintains Buy on Delcath Systems (DCTH) Feb 2026, PT Cut to $19 - Meyka
Delcath Systems Inc (DCTH) Q4 2025 Earnings Call Highlights: Rec - GuruFocus
Delcath targets at least $100M revenue in 2026 while expanding to 40 treatment centers - MSN
Delcath Systems Q4 Earnings Call Highlights - MarketBeat
Earnings Call Summary | Delcath Systems(DCTH.US) Q4 2025 Earnings Conference - 富途牛牛
DCTH: BTIG Lowers Price Target, Maintains Buy Rating for Delcath Systems | DCTH Stock News - GuruFocus
BTIG Research Cuts Delcath Systems (NASDAQ:DCTH) Price Target to $19.00 - MarketBeat
Earnings call transcript: Delcath Systems Q4 2025 sees revenue beat, stock dips - Investing.com Nigeria
Clear Street lowers Delcath Systems stock price target on revised revenue outlook - Investing.com Canada
Delcath Systems Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Delcath Systems, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Biliary Tract Cancer Market: Expanding Revenue Landscape to 2034 – DelveInsight | AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharma, Eisai, Merck - Barchart.com
Delcath (DCTH) Reports Strong Q4 Revenue and Anticipates Future Growth - GuruFocus
DCTH Forecasts Robust Gross Margin for Fiscal Year 2026 - GuruFocus
DCTH: Record revenue, strong growth, and CHOPIN data set stage for further expansion in 2026 - TradingView
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results - BioSpace
DELCATH SYSTEMS, INC. SEC 10-K Report - TradingView
DELCATH SYSTEMS ($DCTH) Releases Q4 2025 Earnings - Quiver Quantitative
Delcath Systems, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Delcath Systems earnings beat by $0.03, revenue topped estimates - Investing.com UK
Delcath Systems (NASDAQ: DCTH) lifts 2025 revenue, sets 2026 guidance - Stock Titan
BRIEF-Delcath Systems Q4 Revenue USD 20.728 Million Vs. IBES Estimate USD 20.3 Million - TradingView
Delcath Systems Q4 2025 Earnings Call Transcript - MarketBeat
Delcath Systems (DCTH) to Release Earnings on Thursday - MarketBeat
0.70%
0.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):